Production of recombinant protein therapeutics in cultivated mammalian cells

By Florian Maria Wurm. Nature Biotechnology, 2004

2,069 citations recorded by the source corpus.

Cultivated mammalian cells have become the dominant system for the production of recombinant proteins for clinical applications because of their capacity for proper protein folding, assembly and post-translational modification. Thus, the quality and efficacy of a protein can be superior when expressed in mammalian cells versus other hosts such as bacteria, plants and yeast. Recently, the productivity of mammalian cells cultivated in bioreactors has reached the gram per liter range in a number of cases, a more than 100-fold yield improvement over titers seen for similar processes in the mid-1980s. This increase in volumetric productivity has resulted mainly from improvements in media composition and process control. Opportunities still exist for improving mammalian cell systems through further advancements in production systems as well as through vector and host cell engineering.

Subfields: Biotechnology, Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/f3574769a93d52de3b57119464cdafd5b527612c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biotechnology

In Genetics

In Molecular Biology

Citations in the corpus

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies (2010, methodology): “Industrial production of mAbs is performed predominantly by recombinant DNA technology, using mammalian cell expression systems,([7,8]) while the first therapeutic mAbs were produced using the hybridoma technique.”
Mammalian cell transfection: the present and the future (2010, background): “The main purpose of transfection is to study the function of genes or gene products, by enhancing or inhibiting specific gene expression in cells, and to produce recombinant proteins in mammalian cells [3].”
Ligand–receptor interaction platforms and their applications for drug discovery (2012, background): “Advances in molecular cloning and cell culture technologies have made it routine to produce many target proteins with high quality, so it is affordable to perform large-scale biochemical analysis of drug--target interactions [3].”